Optic Neuritis RENEW Trial Results
The human monoclonal antibody opicinumab may potentially enhance spontaneous remyelination after acute optic neuritis.
The human monoclonal antibody opicinumab may potentially enhance spontaneous remyelination after acute optic neuritis.
Patients with chronic migraine and comorbidities incur nearly 2 times the health care costs of patients with migraine alone.
The large number of recalls of medical devices has pointed to a need for more active monitoring of product performance from the standpoints of both safety and efficacy.
Reward feedback responses in the brain may be predictive of chronic pain complaints later on.
The FDA released guidance to establish standards for communications about products.
Novel psychosocial therapies such as cognitive behavioral therapy that have been effective in adults with fibromyalgia need additional neuromuscular fitness training to overcome catastrophizing and fear of exercise in adolescents.
Cognitive behavioral therapy is an effective nonpharmacologic treatment that should be considered as a first-line therapy for pediatric migraine.
Treatment of cluster headache by sphenopalatine ganglion stimulation has long-term benefits in the prevention of attacks.
SHUTi represents “an attractive solution to challenges of scalability.”
Most patients required a least a year to completely withdraw from immunotherapy in order to demonstrate a clinical remission.